Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
Immunic presented three posters at the CMSC Annual Meeting highlighting additional data from its Phase 2 CALLIPER trial for vidofludimus calcium in progressive multiple sclerosis. A late-breaking poster introduced a novel 'Confirmed Disability Change' endpoint, showing favorable effects for vidofludimus calcium versus placebo across multiple statistical models, suggesting potential neuroprotective benefits.
Key figures
- Drug Name
- vidofludimus calcium (IMU-838)
- Phase Of Trial
- Phase 2
- Trial name
- CALLIPER
- Patient count
- 467
- Sae rate placebo
- 6.5%
- Teae rate placebo
- 68.5%
- Liver teae placebo
- 5.5%
- Discontinuation rate
- 2.6%
- Sae rate vidofludimus
- 8.1%
- Total exposed to drug
- 3400
- Teae rate vidofludimus
- 69.4%
- Liver teae vidofludimus
- 5.2%
- Phq9 change week48 placebo
- -0.347
- Phq9 change week120 placebo
- -0.525
- Phq9 change week48 vidofludimus
- -0.786
- Phq9 change week120 vidofludimus
- -1.777
- Treatment satisfaction week48 placebo
- 72.88
- Treatment satisfaction week120 placebo
- 79.2
- Treatment satisfaction week48 vidofludimus
- 77.51
- Treatment satisfaction week120 vidofludimus
- 84.69
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.